Home2020-10-19T10:29:51+00:00

Our Mission

Transforming the development of ex vivo cell therapies and pioneering the field of in vivo reprogramming therapies.

Watch Mogrify® Video

About

Mogrify

Mogrify® has developed a proprietary suite of platform technologies that enable systematic identification of the key transcriptomic and epigenetic switches that drive the speed, efficiency and maintenance of cell conversions. MOGRIFY® is a direct cellular conversion platform, which leverages transcriptomic data to identify optimal combinations of transcription factors for the conversion, via enhanced forward reprogramming or transdifferentiation, of any cell type into any other cell type. EpiMOGRIFY is a cell identity platform, which leverages epigenetic data to identify optimal combinations of transcription factors or growth factors required to maintain cell identity and epigenetically support the conversion of cells in chemically defined media. Mogrify is deploying these platforms to develop scalable ex vivo cell therapies and in vivo reprogramming therapies for diseases with a high unmet clinical need.

Learn More

Our

HISTORY

2009

FANTOM 5 LAUNCH

RIKEN scientists launch an international consortium to provide insight into the regulatory landscape of the transcriptome across as many cell states as possible.

2014

MOGRIFY VALIDATION

Collaboration with Jose Polo to test cell conversions begins and three conversions are validated in just several months.

2016

NATURE GENETICS

Mogrify V1 platform and cell conversions results published in Nature Genetics journal featuring on the front page.

2018/2019

GROWTH PHASE

$3.7M seed capital raised, Dr. Darrin M. Disley, OBE appointed as CEO, and Dr. Jane Osbourn, OBE appointed as Chair, hired 40 scientists and raised an additional $16 million in the initial close of Series A funding.

2020

CELL SYSTEMS

EpiMOGRIFY cell identity platform and validation published in Cell Systems journal.

2011

MOGRIFY DEVELOPMENT

Julian Gough and Owen Rackham begin the V1 platform development using the unpublished FANTOM 5 consortium data.

2015

FOUNDATION PATENT

Julian Gough, Owen Rackham, Jose Polo file a patent application for the V1 platform and over 30 direct cell conversions.

2016/2018

INCORPORATION

Mogrify is incorporated in February 2016 by the three academic Co-founders: J. Gough, O. Rackham & J. Polo with pre-seed and grant funding to begin the industrial development and application of the V1 platform.

2020

PROOF OF CONCEPT

First milestone & royalty-bearing deals executed. Appointed Dr. Lorenz Mayr to the Board of Directors and Scientific Advisory Board. Progression of internal programs to in vitro and in vivo proof-of-concept stage.

Our

SCIENCE

Mogrify has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type. Mogrify is applying this approach to address the issues of efficacy, safety and scalability currently associated with ex vivo cell therapy development and manufacturing, as well as pioneering a new class of in vivo reprogramming therapies, positioning the company to address a rapidly growing regenerative medicine market estimated to be worth a $39 billion USD by 2023.

Learn more about MOGRIFY® & EpiMOGRIFY

Mogrify

PARTNERING & INVESTING

Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical need. We are particularly interested in speaking with those with interest in hematological, immunological, ophthalmological as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development, co-development partnerships, and out-licensing of novel cell conversions applicable to non-core markets.

Partnering
Investing

Current

Investors

Ahren Innovation Capital

Ahren LP is an investment fund that supports transformational companies at the cutting edge of deep science and deep tech. The technologies of its Founding Partners are today valued more than $100 billion combined. A group of highly diverse, creative and original thinkers leading their domains, Ahren believes in taking considered risk that will deliver superior rewards— capturing a generational opportunity to provide smart capital to deep technology pioneers. With a philosophy espousing the importance of relationships and trust, Ahren provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable. Ahren Innovation Capital was founded by Alice Newcombe-Ellis, together with Science Partners Sir Shankar Balasubramanian, Professor John Daugman, Professor Zoubin Ghahramani, Professor Steve Jackson, Professor Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter.

Mogrify investor 24haymarket

24HAYMarket

24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. It invests its own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

mogrify investor parkwalk

Parkwalk Advisors

Parkwalk is the largest growth EIS fund manager, backing world-changing technologies emerging from the UK’s leading universities and research institutions. With £250m of assets under management, it has invested in over 100 companies across its flagship Parkwalk Opportunities EIS Fund as well as the award-winning enterprise and innovation funds Parkwalk manages for the Universities of Cambridge, Oxford and Bristol.

Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech and big data

mogrify investor university of bristol

University of Bristol

The University of Bristol Enterprise Fund is an early-stage investment fund backing scientific and technological companies spun out of the University of Bristol or being supported by the University’s SETsquared incubator.

DR. DARRIN M. DISLEY OBE

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises, raising $500 million USD in business financing and closing $600 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Latest

News

View all articles
Go to Top